title: Novel systemic therapies for the treatment of psoriasis.
abstract: BACKGROUND
  The immunopathogenesis of psoriasis has led to the discovery and development of several promising treatment options for psoriasis, including those that target the IL-17 and IL-23 pathways as well as small molecules that act on intracellular signaling pathways including the Janus kinase inhibitor and phosphodiesterase-4 inhibitor. Studies have demonstrated efficacy although long-term risks are not fully known. This review looks at novel systemic therapies for psoriasis that have emerged recently.
  
  
  METHODS
  Systemic treatments for psoriasis that are in the late phase of development were reviewed, with the main focus on the efficacy and adverse effects of individual treatments.
  
  
  CONCLUSIONS
  The future of psoriasis treatment is likely to be based on clinical, genetic and immune biomarkers that will individualize treatment and may potentially optimize disease outcome.
authors.affiliation: a Dermatology Centre, Manchester Academic Health Science Centre, Salford Royal Hospital , University of Manchester, Manchester , UK.|b Department of Dermatology , Changi General Hospital , Singapore.
authors.forename: Ki-Wei
authors.initials: KW
authors.lastname: Tan
authors.affiliation: a Dermatology Centre, Manchester Academic Health Science Centre, Salford Royal Hospital , University of Manchester, Manchester , UK.
authors.forename: Christopher E M
authors.initials: CE
authors.lastname: Griffiths
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D059451:Biosimilar Pharmaceuticals / Q000627:therapeutic use; D000069462:Dimethyl Fumarate / Q000627:therapeutic use; D006801:Humans; D053612:Janus Kinases / Q000037:antagonists & inhibitors; D058988:Phosphodiesterase 4 Inhibitors / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D059451:Biosimilar Pharmaceuticals; D058988:Phosphodiesterase 4 Inhibitors; D053612:Janus Kinases; D000069462:Dimethyl Fumarate
keywords: IL-17; IL-23; JAK inhibitor; biologic; novel; phosphodiesterase-4 inhibitor; psoriasis; small molecules; systemic